Article info
Commentary
Infliximab at diagnosis: moving towards personalisation in paediatric inflammatory bowel disease
- Correspondence to Professor R Mark Beattie, Southampton Children's Hospital, Southampton SO16 6YD, UK; mark.beattie{at}uhs.nhs.uk
Citation
Infliximab at diagnosis: moving towards personalisation in paediatric inflammatory bowel disease
Publication history
- Received February 25, 2021
- Accepted March 5, 2021
- First published March 15, 2021.
Online issue publication
February 02, 2022
Article Versions
- Previous version (2 February 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.